Q1 Earnings Estimate for BNTC Issued By Leerink Partnrs

Benitec Biopharma Inc. (NASDAQ:BNTC) – Analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Benitec Biopharma in a report issued on Monday, October 14th. Leerink Partnrs analyst M. Foroohar expects that the biotechnology company will post earnings per share of ($0.54) for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Benitec Biopharma’s current full-year earnings is ($2.46) per share. Leerink Partnrs also issued estimates for Benitec Biopharma’s Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.34) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.50) EPS and FY2026 earnings at ($1.39) EPS.

Several other research analysts have also recently commented on BNTC. JMP Securities raised their target price on shares of Benitec Biopharma from $16.00 to $18.00 and gave the stock a “market outperform” rating in a report on Monday. Oppenheimer initiated coverage on shares of Benitec Biopharma in a research note on Wednesday. They issued an “outperform” rating and a $35.00 price objective for the company. Leerink Partners started coverage on Benitec Biopharma in a report on Monday, July 22nd. They issued an “outperform” rating and a $13.00 target price for the company. Finally, Guggenheim assumed coverage on Benitec Biopharma in a research report on Thursday, September 12th. They issued a “buy” rating and a $17.00 target price for the company. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $22.60.

Benitec Biopharma Stock Performance

Shares of NASDAQ:BNTC opened at $11.22 on Thursday. The stock has a market capitalization of $105.11 million, a price-to-earnings ratio of -5.87 and a beta of 0.90. Benitec Biopharma has a 1-year low of $2.69 and a 1-year high of $12.89. The company has a 50 day moving average price of $9.18 and a 200 day moving average price of $8.35.

Institutional Investors Weigh In On Benitec Biopharma

Institutional investors and hedge funds have recently modified their holdings of the business. GAMMA Investing LLC grew its position in shares of Benitec Biopharma by 53.0% in the second quarter. GAMMA Investing LLC now owns 5,438 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 1,884 shares during the last quarter. Simplify Asset Management Inc. bought a new stake in Benitec Biopharma during the 2nd quarter valued at approximately $358,000. Janus Henderson Group PLC grew its holdings in Benitec Biopharma by 35.5% in the 1st quarter. Janus Henderson Group PLC now owns 244,491 shares of the biotechnology company’s stock valued at $1,266,000 after buying an additional 64,092 shares during the last quarter. Finally, Nantahala Capital Management LLC bought a new position in Benitec Biopharma in the 2nd quarter worth approximately $5,881,000. Institutional investors and hedge funds own 52.19% of the company’s stock.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.